Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA User Fee Renewals Remain On Schedule Despite Coronavirus

Apr 02 2020

• By Derrick Gingery

User Fee Reauthorization Preview 2020 — Preparations for the upcoming user fee reauthorizations continue despite coronavirus challenges. • Source: File photo

Related Content

Predicting The User Fee Reauthorization Schedule

Feb 04 2020

BsUFA III: Could Regulatory Science Research Emerge With Other Tweaks?

Feb 04 2020

PDUFA VII: Will Gene Therapy's Rise Influence Talks?

Feb 04 2020

GDUFA III: How Much Of A Fee Increase Can Industry Stomach?

Feb 04 2020

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Mar 29 2020

US FDA Exploring Virtual Advisory Cmtes.; Might Sponsors Want To Wait For In-Person Meetings?

Apr 02 2020

As US FDA Settles Into Teleworking, Will Application Reviews Be Affected?

Mar 24 2020

US FDA Freezes Inspections And Outside Meetings. Will Review Goal Dates Stay Put?

Mar 11 2020

Additional Topics

United States User Fees Drug Review Coronavirus COVID-19 Regulation FDA BioPharmaceutical

More from User Fees

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.